Abstract: The present invention relates to new crystalline molecular sieve SSZ-75 having STI framework topology prepared using a tetramethylene-1,4-bis-(N-methylpyrrolidinium) dication as a structure-directing agent and its use in treating engine exhaust.

Abstract: A lean NOx trap composition. The lean NOx trap composition utilizes ruthenium in place of higher cost metals such as platinum. The lean NOx trap composition provides high NOx storage efficiency and high NOx conversion efficiency when incorporated in a lean NOx trap. A method of removing harmful gases using the lean NOx trap composition is also described.

Abstract: The present invention relates to a method for separation and recycling of pure sulfur dioxide from a gaseous mixture in the IS cycle. More specifically, the present invention relates to a method for separation and recycling of pure sulfur dioxide from a gaseous mixture in the IS cycle using an ionic liquid under a specific condition. When compared with the conventional amine-based absorbent, the use of the ionic liquid enables continuous absorption and stripping of SO2 even at high temperature, and enables a reversible absorption of SO2 without loss, decomposition or degradation of a solvent due to good chemical stability, thereby enabling separation and recycling of pure SO2 from a gaseous mixture in the IS cycle.

Abstract: Provided are methods for producing carbonate-containing compositions comprising silicon-based material (e.g., pozzolanic material) from a source of carbon dioxide, a divalent cation-containing solution, and a source of proton-removing agents. In such methods, divalent cations of the divalent cation-containing solution are provided by digestion of material comprising metal silicates. Also provided are methods for producing carbonate-containing compositions comprising little or no silicon-based material. In such methods, silicon-based material (e.g., silica, unreacted or undigested silicates, aluminosilicates, etc.) may be separated and processed separately from carbonate-containing compositions. Silicon-based material and carbonate-containing material may be blended at a later stage to produce a pozzolanic material, which may be further processed and blended with, for example, Portland cement.

Abstract: A carbon nanotube array includes a plurality of carbon nanotubes. Each of the carbon nanotubes has a plurality of line marks formed on each of the carbon nanotubes. The line marks transversely extend across the carbon nanotubes. The line marks of each of the carbon nanotubes are spaced apart from each other.

Abstract: This disclosure relates to morphological control of carbon nanotubes, to form shapes, including, inter alia, nanosprings, nanocoils and nanohooks of desired shape, diameter, chirality and /or pitch wherein a desired morphological design may be manipulated with spatially, sequential time varying electric fields formed by electrode arrays located and activated near the CNT growth substrate. These forms may be employed in a myriad of various applications, including, micro electromechanical systems and advanced microelectronic interconnects.

Abstract: The invention is directed to carbon fibers having high tensile strength and modulus of elasticity. The invention also provides a method and apparatus for making the carbon fibers. The method comprises advancing a precursor fiber through an oxidation oven wherein the fiber is subjected to controlled stretching in an oxidizing atmosphere in which tension loads are distributed amongst a plurality of passes through the oxidation oven, which permits higher cumulative stretches to be achieved. The method also includes subjecting the fiber to controlled stretching in two or more of the passes that is sufficient to cause the fiber to undergo one or more transitions in each of the two or more passes. The invention is also directed to an oxidation oven having a plurality of cooperating drive rolls in series that can be driven independently of each other so that the amount of stretch applied to the oven in each of the plurality of passes can be independently controlled.

Abstract: A method for producing cadmium telluride from elemental cadmium and elemental tellurium is disclosed. For example, the method disclosed can be used for producing multi-kilogram batches of cadmium telluride in a few hours.

Abstract: A method for removing hydrogen sulfide from a sour gas stream comprising hydrogen sulfide by oxidizing hydrogen sulfide in a converter by contacting the sour gas stream with an aqueous catalytic solution, thereby producing a desulfurized gas stream and a liquid stream comprising reduced catalyst and elemental sulfur, introducing an oxidant and the liquid stream comprising reduced catalyst and elemental sulfur into a high shear device and producing a dispersion wherein the mean bubble diameter of the oxidant gas in the dispersion is less than about 5 ?m, introducing the dispersion into a vessel from which a sulfur-containing slurry is removed and a regenerated catalyst stream is removed, wherein the sulfur slurry comprises elemental sulfur and aqueous liquid, and recycling at least a portion of the regenerated catalyst stream to the converter. A system of apparatus for carrying out the method is also provided.

Abstract: To provide a process for producing a lithium-containing composite oxide for a positive electrode for a lithium secondary battery, which is excellent in the volume capacity density, safety, charge and discharge cycle durability and low temperature characteristics. A process for producing a lithium-containing composite oxide represented by the formula LipNxMmOzFa (wherein N is at least one element selected from the group consisting of Co, Mn and Ni, M is at least one element selected from the group consisting of Al, alkaline earth metal elements and transition metal elements other than N, 0.9?p?1.2, 0.97?x<1.00, 0<m?0.03, 1.9?z?2.2, x+m=1 and 0?a?0.

Abstract: Disclosed is a processes for the production of relatively high purity alkaline earth metal oxides, such as SrO, from relatively low purity forms of carbonated or other oxygenated forms of such metals, such as strontium carbonate. The relatively low purity material is exposed to conditions under which at least a portion of the metal contained therein is converted to a salt that is more readily solvated in a provided solvent than the starting material, while at the same time not substantially increasing the solubility of at least one or more of the impurities in such selected solvent. This step is then preferably followed by removal of solid or otherwise un-dissolved impurities from the solution. After the removal step, the solution is preferably exposed to conditions effective to form a relatively insoluble salt of the alkaline earth metal, such as a strontium salt. The insoluble salt is also preferably one that can be readily and effectively converted to the desired alkaline earth metal oxide, preferably SrO.

Abstract: A material mixture is disclosed for storage of hydrogen for a hydrogen-using device and release of hydrogen on demand of the hydrogen-using device, especially by heating of the mixture. Such a mixture suitably comprises a solid hydrogen-containing lithium compound (e.g. LiBH4) and a solid magnesium compound, MgX, the magnesium compound being reactive with the lithium compound to release hydrogen and yield solid by products containing lithium and X. X may include one or more of F, Cl, OH, O, S, Se, Si, CO3, SO4, Cu, Ge, Ni, (OH)Cl, and P2O7.

Abstract: Composition for diagnostic or therapeutic use which comprises an assembly comprising an active agent. The assembly comprises a liposome and a plurality of micellar components associated thereto, said micellar components being associated to the outer surface of the envelope of said liposome through a substantially electrostatic interaction, When an active compound is incorporated into the micelles, a substantial amount of said active compound can be linked to a singe liposome. Furthermore, the presence of the outer micellar layer allows to increase the residence time of said liposome in the blood stream.

Abstract: The present invention relates to a LOX-GFP marker and methods of analyzing tumor burden in ascites or in lung. The invention also relates to a new LOX-GFP-LM cell line which demonstrates increased lung metastasis. The methods of the invention result in better quantitative tumor burden assessment and improved efficacy evaluation. These improved models provide a feasible alternative for ascites or experimental metastasis evaluation of novel cancer therapeutics.

Abstract: A convenient to use test method for comparing the relative affinity of surfactants for the skin employs a solid or semisolid matrix for associating a dye or pigment with the skin. The dye or pigment has an affinity to either the skin or a surfactant adsorbed on the skin during personal cleansing. The matrix may include a reagent soluble polymer film or temporary tattoo.

Abstract: The present invention provides various pharmaceutically active topical delivery compositions. In particular, compositions of the present invention are present in a pressurized container comprising a quick-breaking alcoholic foaming agent, such that when the composition is released, i.e., dispensed, from the pressurized container, a quick-breaking temperature sensitive foam is formed. In addition, the present invention provides various aspects related to such compositions, including methods for modulating a foam characteristic, methods for improving the shelf-life of a pharmaceutically active compound, methods for the percutaneous treatment of various diseases, infections, and illnesses, and methods for evaluating foam characteristics.

Abstract: A topical administration carrier composition including water, glycerin and polysorbate, suitable for use in formulations with active ingredient compositions containing active ingredients such as minoxidil that are susceptible to systemic penetration, and solvents that are susceptible to evaporative loss, when the active ingredient composition is topically applied to the body. The carrier formulation retards the evaporative losses of the solvent component(s) and systemic migration losses of the active ingredient composition, to provide sustained topical action, in relation to formulations lacking the carrier composition of the invention.

Abstract: IL-10 sequence variants are disclosed that retain the therapeutically desirable anti-inflammatory properties of wild-type IL-10 but do not retain the hemoatopoeitic cell regulatory and cell proliferative activities. The mutant IL-10 polypeptides of the invention are used in methods of treating diseases involving inflammatory response, including neuropathic pain and other neurological disorders.

Abstract: Agents and methods to alter rAAV transduction are provided.

Abstract: The invention relates to Adeno-associated virus vectors. In particular, it relates to Adeno-associated virus vectors with modified capsid proteins and materials and methods for their preparation and use.

Abstract: The present invention provides methods and vector systems for the generation of chimeric recombinant adenoviruses. These hybrid adenoviruses contain a genome that is derived from different adenovirus serotypes. In particular, novel hybrid adenoviruses are disclosed with improved properties for gene therapy purposes. These properties include: a decreased sensitivity towards neutralizing antibodies, a modified host range, a change in the titer to which adenovirus can be grown, the ability to escape trapping in the liver upon in vivo systemic delivery, and absence or decreased infection of antigen presenting cells (APC) of the immune system, such as macrophages or dendritic cells. These chimeric adenoviruses thus represent improved tools for gene therapy and vaccination since they overcome the limitations observed with the currently used serotype subgroup C adenoviruses.

Abstract: The invention concerns the use of non-pathogenic hydrogenotrophic acetogenic bacterial strains for preparing a composition for treating or preventing gastrointestinal disorders associated with productions of digestive gases and/or for modulating the microbial balance of the digestive ecosystem in a mammal. The invention also concerns said pharmaceutical or food compositions, and the methods for monitoring and preparing said strains.

Abstract: The invention relates to inducing an immune response toward tumor associated antigens and in particular to the administration of high molecular weight isolates of autologous urine either alone, with adjuvants, or with antigen presenting cells. The antigen presenting cells have been cocultured with isolates of autologous urine. The invention can also be used to treat cachexia in cancer or AIDS patients.

Abstract: A method of promoting neuronal regeneration includes administering an agent to at least one neural cell in contact with at least one neural cell growth inhibiting component in an amount effective to promote neuronal regeneration. The agent is selected from the group consisting of a Class I Rho family GTPase, a C1 activator, a Class II Rho family GTPase, and a C2 inhibitor.

Abstract: Adsorbent carbon microspheres are administered to treat irritable bowel syndrome or symptoms associated with irritable bowel syndrome.

Abstract: Disclosed are antibodies that provide superior anti-coagulant activity by binding native human TF with high affinity and specificity. Also disclosed are methods of using such antibodies to reduce cancer cell tissue factor activity and to detect cancer cells that express TF.

Abstract: The identification of a highly conserved, immunologically accessible antigen at the surface of Neisseria facilitates treatment, prophylaxis, and diagnosis of Neisseria diseases. This antigen is highly resistant to Proteinase K and has an apparent molecular weight of 22 kDa on SDS-PAGE. Specific polynucleotides encoding proteins of this class have been isolated from three Neisseria meningitidis strains and from one Neisseria gonorrhoeae strain. These polynucleotides have been sequenced, and the corresponding full-length amino acid sequences of the encoded polypeptides have been deduced. Recombinant DNA methods for the production of the Neisseria surface protein, and antibodies that bind to this protein are also disclosed.

Abstract: The present invention is directed to novel polypeptides having sequence identity with IL-17 and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders.

Abstract: Provided are fusion polypeptides comprising an engineered antibody and a stress protein that bind to antigens with high affinity, are highly immunogenic, exhibit MHC class I priming and are able to be produced in non-mammalian cells, such as E. coli.

Abstract: The present invention relates to an oral composition and an immunogenic composition for the suppression of the pathogenic effects of the intra-oral bacterium Porphyromonas gingivalis associated with periodontal disease.

Abstract: The invention relates to a method of removing 3-deoxyglucosone and other alpha-dicarbonyl sugars from skin. The invention further relates to methods of inhibiting production and function of 3-deoxyglucosone and other alpha-dicarbonyl sugars in skin. The invention also relates to methods of treating 3-deoxyglucosone and other alpha-dicarbonyl sugars associated diseases and disorders of skin.

Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.

Abstract: Compositions and methods for the therapy and diagnosis of cancer, particularly lung cancer, are disclosed. Illustrative compositions comprise one or more lung tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly lung cancer.

Abstract: Embodiments of the present invention generally relate to proteins derived from white spot syndrome virus, nucleic acid sequences encoding them, and their use in the manufacture of a vaccine for prophylaxis and/or treatment of white spot syndrome in crustaceans.

Abstract: A fusion protein, derived from P. falciparum Glutamate-rich protein (GLURP) genetically coupled to P. falciparum Merozoite surface protein 3 (MSP3) was produced in Lactococcus lactis as a secreted recombinant GLURP-MSP3 hybrid protein and experiments showed that the GLURP-part of the hybrid increased the overall antibody response. Immunizations with the hybrid protein consistently generated a stronger antibody response against the individual GLURP and MSP3 domains than a mixture of the two recombinant molecules injected at one site or the individual recombinant molecules injected simultaneously at two different sites. The difference was most pronounced for the MSP3-specific antibody response suggesting that T cell epitopes located in the GLURP RO-region provide help for B-cell epitopes in the MSP3 region.

Abstract: The present invention provides an antioxidant and a whitening agent having high safety, and a external preparation for skin using the same. The antioxidant and whitening agent comprise, as an effective component, one or more extracts from Basidiomycetes selected from the group consisting of Pleurotus abalonus, Pholiota squarrosa, Onnia orientalis, Astraeus hygrometricus and Pleurotus nebrodensis . These extracts have a free radical capturing ability and are useful for suppressing skin oxidation and for preventing and improving skin aging. In addition, the extracts have a tyrosinase activity inhibiting action and can suppress the melanin generation. Since the fruit bodies of these Basidiomycetes have been used for edible purpose and have high safety, they can be used preferably for an external preparation for skin.

Abstract: A method of treating autism using a probiotic composition including the bacilli (1) Bacillus subtilis, (2) Bacillus coagulans, and (3) Enterococcus faecium. The composition may further include a carrier medium, such as fructo-oligo-saccharides (FOS), as incorporated in a dose form such as a pill, capsule, powder or sachet. The compositions of the invention may be usefully employed as health or nutritional supplements, food additives, or therapeutic agents for combating a wide variety of physiological disorders.

Abstract: Site-specific Listeria integration vectors and methods for their use are provided. The subject vectors include a bacteriophage integrase gene and a bacteriophage attachment site, where in many embodiments the bacteriophage that is the source of these elements is a listeriophage. In certain embodiments, the subject vectors further include a multiple cloning site, where the multiple cloning site may further include a polypeptide coding sequence, e.g., for a heterologous antigen. The subject vectors and methods find use in a variety of different applications, including the study of Listeria species and the preparation of Listeria vaccines.

Abstract: The present invention provides an immunogenic conjugate comprising biologically deacylated gram-negative bacterial moieties linked to D. discoideum proteinase 1, as well as novel subunits thereof, and methods of making and using the conjugates in vaccines to treat sepsis and other infectious complications.

Abstract: Compositions and methods for treating, preventing and diagnosing Helicobacter infection are disclosed. The methods use proteins and/or nucleic acids derived from Helicobacter cerdo, a new pathogen isolated from swine. In addition, porcine models for studying bacterial gastritis and gastric and duodenal ulcer disease caused by Helicobacter pathogens, such as H. pylori and H. cerdo are described, as well as methods of identifying vaccines and compounds for treating and/or preventing Helicobacter infection using the animal models. Also described are methods of preventing Helicobacter infection in swine, such as infection caused by H. cerdo, using immunogenic proteins and nucleic acids derived from Helicobacter pathogens, such as H. pylori.

Abstract: The present invention relates to cholesterol-lowering preparations, in particular to a bacterial preparation for use as a medicament for lowering of the blood cholesterol level. The present invention provides inter alia a preparation of Rhodospirillum spp. and/or Phaeospirillum with cholesterol-lowering effects, food supplements and foodstuffs comprising said preparation and methods for the preparation and use thereof.

Abstract: Compositions comprising activatable recombinant neurotoxins and polypeptides derived therefrom. The invention also comprises nucleic acids encoding such polypeptides, and methods of making such polypeptides and nucleic acids.

Abstract: Botulinum toxin, among other presynaptic neurotoxins is used for the treatment and prevention of migraine and other headaches associated with vascular disorders. Presynaptic neurotoxins are delivered focally, targeting the sphenopalatine ganglion. Exemplary delivery is carried out by way of injection.

Abstract: The GapC plasmin binding protein genes of Streptococcus dysgalactiae (S. dysgalactiae), Streptococcus agalactiae (S. agalactiae), Streptococcus uberis (S. uberis), Streptococcus parauberis (S. parauberis), and Streptococcus iniae (S. iniae) are described, as well as the recombinant production of the GapC proteins therefrom. Also described is the use of the GapC proteins from those species in vaccine compositions to prevent or treat bacterial infections in general, and mastitis in particular.

Abstract: The present invention provides compositions useful in preparing and/or serving as antitoxins against Bacillus anthracis, the causative agent of anthrax. The present invention also provides polypeptides and polynucleotides relating to the capillary morphogenisis gene 2 (CMG-2), vectors containing the polynucleotides and polypeptides, and host cells containing related polynucleotide molecules, all used in association with the treatment of, or the research and development of treatments for anthrax. The present invention also relates to methods for identifying molecules that bind CMG-2 and molecules that reduce the toxicity of anthrax toxin. Finally, the present invention provides methods for treating human and non-human animals suffering from anthrax.

Abstract: Polypeptides comprising non-typeable Haemophilus influenzae (NTHi) amino acid sequences. Over 2500 specific NTHi proteins are disclosed. The invention also provides related polypeptides, nucleic acids, antibodies and methods. These can all be used in medicine for treating or preventing disease and/or infection caused by H. influenzae, such as otitis media.

Abstract: Malaria in humans is caused by infection with Plasmodium species parasites including P. vivax. The biology and immunobilogy of P. vivax is distinct from that of P. falciparum. Provided are unique synthetic polypeptides and DNA molecules which encode them. Each of these molecules correspond to regions of the circumsporozoite protein of P. vivax. Each molecule comprises sequences corresponding to several repeats of the central region of the Pv 210 variant fused to sequences corresponding to several repeats of the central region of the Pv 247 variant. Each molecule additionally comprises sequences corresponding to either the amino terminus, the carboxy terminus, or both the amino and carboxy termini of the PvCSP. Also provided are vaccines comprising these unique sequences and methods of using these vaccines and sequences to prevent and treat Pv malaria.

Abstract: The present invention relates to liposome formulations that are physically stable. In particular the present invention relates to steric stabilization of cationic liposomes by incorporating glycolipids into the liposomes. The stabilized liposomes can be used either as an adjuvant for antigenic components or as a drug delivery system. In particular the invention relates to vaccines with adjuvants in aqueous media for immunization, where the final product is stable.

Abstract: The invention describes a new class of crystalline silica material having two levels or porosity and structural order. At the first level, building units are nanoslabs of uniform size having zeolite framework. At the second structural level, nanoslabs are assembled, e.g. linked through their corners, edges or faces following patterns imposed by interaction with cationic surfactant or triblock copolymer molecules. After evacuation of these molecules, microporosity is obtained inside the nanoslabs, and a precise mesoporosity between the nanoslabs depending on the tiling pattern of the zeolite nanoslabs, as evidenced by X-ray diffraction. These materials are useful for the fixation of biologically active species, such as poorly soluble drugs.

Abstract: The present invention relates to a method for arresting, protecting and/or preserving an organ which includes administering effective amounts of (i) a potassium channel opener or agonist and/or an adenosine receptor agonist and (ii) local anaesthetic to a subject in need thereof. The present invention also relates to a method for arresting, protecting and/or preserving an organ which comprises adding a composition which includes effective amounts of (i) a potassium channel opener or agonist and/or an adenosine receptor agonist and (ii) a local anaesthetic to the organ. The present invention further provides a pharmaceutical or veterinary composition which includes effective amounts of (i) a potassium channel opener or agonist and/or an adenosine receptor agonist and (ii) a local anaesthetic.